Can a new heart pump outperform the standard during High-Risk angioplasty?

NCT ID NCT06853470

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether a new device called SynFlow 3.0 can safely support the heart during high-risk angioplasty (a procedure to open blocked coronary arteries) as well as the standard VA-ECMO device. About 222 people with severe coronary artery disease and a weakened heart (ejection fraction ≤35%) will be randomly assigned to receive either SynFlow 3.0 or VA-ECMO during their procedure. The study will compare rates of major adverse events and other outcomes to see if SynFlow 3.0 is a viable alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SynFlow 3.0, a percutaneous left ventricular-assist device, compared with VA-ECMO circulatory support during high-risk PCI
What this could lead to
If SynFlow 3.0 proves as safe and effective as VA-ECMO, it could offer a less invasive option to support the heart during high-risk angioplasty, potentially improving outcomes and recovery.
What could go wrong
This is an early-stage trial with a limited number of patients, and the device may not perform as well as expected. There are also inherent risks of any heart-support procedure, including bleeding, infection, or device-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERIAL DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.